Celsion To Report Clinical Trial Update Of ThermoDox(R) In Recurrent Chest Wall Breas
 

Celsion Corporation (NASDAQ: CLSN) today announced that clinical data from its ThermoDox® Phase 1 Recurrent Chest Wall (RCW) Breast Cancer study will be presented by Duke University Medical Center researchers at the Society for Thermal Medicine 2009 Annual Meeting in Tucson, Arizona on April 3-7, 2009.

More...

"ThermoDox® has also demonstrated remarkable evidence of efficacy in a Phase 1 study for primary liver cancer. "

I wonder if this might translate into efficacy with BC mets to the liver.